XOMA•benzinga•
XOMA Royalty Purchases Future Mezagitamab Royalty And Milestone Interests Held By BioInvent For $20M At Closing, With Total Transaction Of Up To $30M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 27, 2025 by benzinga